Real-Time PCR Chemistries Key to Luminex's $34M EraGen Acquisition

Two years after Luminex and EraGen ended a licensing and distribution agreement that had coupled Luminex's bead-based detection system with EraGen's multiplex PCR chemistry, the companies will reunite through Luminex's planned $34 million acquisition of Eragen.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.